<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37479879</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>02</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1591-9528</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Clinical and experimental medicine</Title><ISOAbbreviation>Clin Exp Med</ISOAbbreviation></Journal><ArticleTitle>Interactions and clinical implications of serological and respiratory variables 3&#xa0;months after acute COVID-19.</ArticleTitle><Pagination><StartPage>3729</StartPage><EndPage>3736</EndPage><MedlinePgn>3729-3736</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10238-023-01139-5</ELocationID><Abstract><AbstractText>Medical follow-up of symptomatic patients after acute Coronavirus Disease 2019 (COVID-19) results in major burdens on patients and healthcare systems. The value of serological markers as part of this follow-up remains undetermined. We aimed to evaluate the clinical implications of serological markers for follow-up of acute COVID-19. For this purpose, we conducted an observational cohort study of patients 3&#xa0;months after acute COVID-19. Participants visited a respiratory-clinic between October 2020 and March 2021, and completed pulmonary function tests (PFTs), serological tests, symptom-related questionnaires, and chest CT scans. Overall, 275 patients were included at a median of 82&#xa0;days (IQR 64-111) post infection. 162 (59%) patients had diffusing capacity for carbon monoxide corrected for hemoglobin (DLCOc) below 80%, and 69 (25%) had bilateral chest abnormalities on CT scan. In multivariate analysis, anti-S levels were an independent predictor for DLCOc (&#x3b2;&#x2009;=&#x2009;-&#x2009;0.14, p&#x2009;=&#x2009;0.036). Anti-S levels were also associated with severe COVID-19 and older age, and correlated with anti-nucleocapsid (r&#x2009;=&#x2009;0.30, p&#x2009;&lt;&#x2009;0.001) and antibodies to receptor binding domain (RBD, r&#x2009;=&#x2009;0.37, p&#x2009;&lt;&#x2009;0.001). Other serological variables were not associated with clinical outcomes. In conclusion, symptomatic patients 3-months after COVID-19 had high respiratory symptomatic burden, in which anti-S levels were significantly associated with previous severe COVID-19 and DLCOc.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Freund</LastName><ForeName>Ophir</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>The Institute of Pulmonary Medicine, Tel-Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Waizman 6, Tel Aviv, Israel. ophir068@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Breslavsky</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Pulmonary Medicine, Barzilai University Medical Center, Ashkelon, and Ben-Gurion University of the Negev, Beer-Sheva, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fried</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Institute of Pulmonary Medicine, Tel-Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Waizman 6, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Givoli-Vilensky</LastName><ForeName>Rotem</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen-Rubin</LastName><ForeName>Shira</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zacks</LastName><ForeName>Nadav</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kleinhendler</LastName><ForeName>Eyal</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>The Institute of Pulmonary Medicine, Tel-Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Waizman 6, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Unterman</LastName><ForeName>Avraham</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The Institute of Pulmonary Medicine, Tel-Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Waizman 6, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frydman</LastName><ForeName>Shir</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Institute of Pulmonary Medicine, Tel-Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Waizman 6, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wand</LastName><ForeName>Ori</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Division of Pulmonary Medicine, Barzilai University Medical Center, Ashkelon, and Ben-Gurion University of the Negev, Beer-Sheva, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bilenko</LastName><ForeName>Natalya</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Office of Southern District, Ministry of Health, Ashkelon, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bar-Shai</LastName><ForeName>Amir</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The Institute of Pulmonary Medicine, Tel-Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Waizman 6, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Clin Exp Med</MedlineTA><NlmUniqueID>100973405</NlmUniqueID><ISSNLinking>1591-8890</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antibodies</Keyword><Keyword MajorTopicYN="N">Long-COVID</Keyword><Keyword MajorTopicYN="N">Monitoring</Keyword><Keyword MajorTopicYN="N">Pulmonary function tests</Keyword><Keyword MajorTopicYN="N">Respiratory</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Serological variables</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>2</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>22</Day><Hour>10</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>21</Day><Hour>23</Hour><Minute>28</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37479879</ArticleId><ArticleId IdType="doi">10.1007/s10238-023-01139-5</ArticleId><ArticleId IdType="pii">10.1007/s10238-023-01139-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global prevalence of post-coronavirus disease 2019 (COVID-19) condition or long COVID: a meta-analysis and systematic review. J Infect Dis. 2022;226(9):1593&#x2013;607.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac136</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Mahoney LL, Routen A, Gillies C, et al. The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: a systematic review and meta-analysis. EClinicalMedicine. 2023;55: 101762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101762</ArticleId><ArticleId IdType="pubmed">36474804</ArticleId></ArticleIdList></Reference><Reference><Citation>Raghu G, Wilson KC. COVID-19 interstitial pneumonia: monitoring the clinical course in survivors. Lancet Respir Med. 2020;8(9):839&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30349-0</ArticleId><ArticleId IdType="pubmed">32758440</ArticleId><ArticleId IdType="pmc">7398671</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutler DM. The Costs of Long COVID. JAMA Heal Forum. 2022;3(5):e221809&#x2013;e221809. https://doi.org/10.1001/jamahealthforum.2022.1809 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamahealthforum.2022.1809</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutler DM, Summers LH. The COVID-19 pandemic and the $16 trillion virus. JAMA. 2020;324(15):1495&#x2013;6. https://doi.org/10.1001/jama.2020.19759 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.19759</ArticleId><ArticleId IdType="pubmed">33044484</ArticleId><ArticleId IdType="pmc">7604733</ArticleId></ArticleIdList></Reference><Reference><Citation>Freund O, Azolai L, Sror N, et al. Diagnostic delays among COVID-19 patients with a second concurrent diagnosis. J Hosp Med. 2023;18(4):321&#x2013;8. https://doi.org/10.1002/jhm.13063 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jhm.13063</ArticleId><ArticleId IdType="pubmed">36779316</ArticleId></ArticleIdList></Reference><Reference><Citation>Anastasio F, Barbuto S, Scarnecchia E, et al. Medium-term impact of COVID-19 on pulmonary function, functional capacity and quality of life. Eur Respir J. 2021;58(3).</Citation></Reference><Reference><Citation>Peluso MJ, Deitchman AN, Torres L, et al. Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms. Cell Rep. 2021;36(6): 109518.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109518</ArticleId><ArticleId IdType="pubmed">34358460</ArticleId><ArticleId IdType="pmc">8342976</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan A, Martinez-Cajas J, Yip PM, et al. Evaluation and comparison of four quantitative SARS-CoV-2 serological assays in COVID-19 patients and immunized healthy individuals, cancer patients, and patients with immunosuppressive therapy. Clin Biochem. 2023;116:1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinbiochem.2023.02.010</ArticleId><ArticleId IdType="pubmed">36849050</ArticleId><ArticleId IdType="pmc">9968448</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogh K, Larsen TG, Hansen CB, et al. Self-reported long COVID and its association with the presence of SARS-CoV-2 antibodies in a danish cohort up to 12 months after infection. Microbiol Spectr. 2022;10(6): e0253722.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/spectrum.02537-22</ArticleId><ArticleId IdType="pubmed">36350150</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Abell&#xe1;n J, Padilla S, Fern&#xe1;ndez-Gonz&#xe1;lez M, et al. Antibody response to SARS-CoV-2 is associated with long-term clinical outcome in patients with COVID-19: a longitudinal study. J Clin Immunol. 2021;41(7):1490&#x2013;501. https://doi.org/10.1007/s10875-021-01083-7 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-021-01083-7</ArticleId><ArticleId IdType="pubmed">34273064</ArticleId><ArticleId IdType="pmc">8285689</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention (CDC). Antibody testing interim guidelines for COVID-19 antibody testing in clinical and public health settings 2022 [cited 2023 Mar 4]. https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing/antibody-tests-guidelines.html .</Citation></Reference><Reference><Citation>Zhao Y-M, Shang Y-M, Song W-B, et al. Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. EClinicalMedicine. 2020;25: 100463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2020.100463</ArticleId><ArticleId IdType="pubmed">32838236</ArticleId><ArticleId IdType="pmc">7361108</ArticleId></ArticleIdList></Reference><Reference><Citation>Drake TM, Riad AM, Fairfield CJ, et al. Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study. Lancet. 2021;398(10296):223&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00799-6</ArticleId><ArticleId IdType="pubmed">34274064</ArticleId><ArticleId IdType="pmc">8285118</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institutes of Health. COVID-19 treatment guidelines [cited 2021 Jan 12]. https://www.covid19treatmentguidelines.nih.gov/ .</Citation></Reference><Reference><Citation>Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId><ArticleId IdType="pmc">7833295</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustin M, Schommers P, Stecher M, et al. Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. Lancet Reg Health Eur. 2021;6:100122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100122</ArticleId><ArticleId IdType="pubmed">34027514</ArticleId><ArticleId IdType="pmc">8129613</ArticleId></ArticleIdList></Reference><Reference><Citation>Guler SA, Wohlfarth E, Berezowska S, Geiser TK, Ebner L, Funke-Chambour M. Performance of a diagnostic algorithm for fibrotic hypersensitivity pneumonitis. A case&#x2013;control study. Respir Res. 2021;22(1):1&#x2013;7. https://doi.org/10.1186/s12931-021-01727-7 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-021-01727-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, Li Z, Wang B, et al. Prognosis and antibody profiles in survivors of critical illness from COVID-19: a prospective multicentre cohort study. Br J Anaesth. 2022;128(3):491&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bja.2021.11.024</ArticleId><ArticleId IdType="pubmed">34980470</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133&#x2013;46. https://doi.org/10.1038/s41579-022-00846-2 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId><ArticleId IdType="pmc">9839201</ArticleId></ArticleIdList></Reference><Reference><Citation>Faverio P, Luppi F, Rebora P, et al. Six-month pulmonary impairment after severe COVID-19: a prospective, multicentre follow-up study. Respiration. 2021;100(11):1078&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000518141</ArticleId><ArticleId IdType="pubmed">34515212</ArticleId></ArticleIdList></Reference><Reference><Citation>Legros V, Denolly S, Vogrig M, et al. A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity. Cell Mol Immunol. 2021;18(2):318&#x2013;27. https://doi.org/10.1038/s41423-020-00588-2 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-020-00588-2</ArticleId><ArticleId IdType="pubmed">33408342</ArticleId></ArticleIdList></Reference><Reference><Citation>Muecksch F, Wise H, Batchelor B, et al. Longitudinal serological analysis and neutralizing antibody levels in coronavirus disease 2019 convalescent patients. J Infect Dis. 2021;223(3):389&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiaa659</ArticleId><ArticleId IdType="pubmed">33140086</ArticleId></ArticleIdList></Reference><Reference><Citation>Freund O, Weiss TE, Tau L, et al. Safety and outcomes of an early discharge strategy with oxygen home therapy in stable severe COVID-19 patients. Infect Dis (Lond, Engl). 2023;55(4):292&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/23744235.2023.2168047</ArticleId></ArticleIdList></Reference><Reference><Citation>Freund O, Tau L, Weiss TE, et al. Associations of vaccine status with characteristics and outcomes of hospitalized severe COVID-19 patients in the booster era. PLoS ONE. 2022;17(5):e0268050. https://doi.org/10.1371/journal.pone.0268050 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0268050</ArticleId><ArticleId IdType="pubmed">35536849</ArticleId><ArticleId IdType="pmc">9089907</ArticleId></ArticleIdList></Reference><Reference><Citation>Bichara CDA, da Silva Gra&#xe7;a Amoras E, Vaz GL, et al. Dynamics of anti-SARS-CoV-2 IgG antibodies post-COVID-19 in a Brazilian Amazon population. BMC Infect Dis. 2021;21(1):443. https://doi.org/10.1186/s12879-021-06156-x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-021-06156-x</ArticleId><ArticleId IdType="pubmed">33992073</ArticleId><ArticleId IdType="pmc">8122196</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerum TV, Maltzahn NN, Aukrust P, et al. Persistent pulmonary pathology after COVID-19 is associated with high viral load, weak antibody response, and high levels of matrix metalloproteinase-9. Sci Rep. 2021;11(1):23205. https://doi.org/10.1038/s41598-021-02547-x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-02547-x</ArticleId><ArticleId IdType="pubmed">34853380</ArticleId><ArticleId IdType="pmc">8636497</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia X, Cao S, Lee AS, et al. Anti-nucleocapsid antibody levels and pulmonary comorbid conditions are linked to post-COVID-19 syndrome. JCI Insight. 2022;7(13).</Citation></Reference><Reference><Citation>Guler SA, Ebner L, Aubry-Beigelman C, et al. Pulmonary function and radiological features 4 months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung study. Eur Respir J. 2021;57(4).</Citation></Reference><Reference><Citation>Huang Y, Tan C, Wu J, et al. Impact of coronavirus disease 2019 on pulmonary function in early convalescence phase. Respir Res. 2020;21(1):163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-020-01429-6</ArticleId><ArticleId IdType="pubmed">32600344</ArticleId><ArticleId IdType="pmc">7323373</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X, Liu X, Zhou Y, et al. 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. Lancet Respir Med. 2021;9(7):747&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00174-0</ArticleId><ArticleId IdType="pubmed">33964245</ArticleId><ArticleId IdType="pmc">8099316</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>